Linked Life Data

21145871

Source:http://linkedlifedata.com/resource/pubmed/id/21145871

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2011-4-18
pubmed:abstractText
Based on the success of sorafenib, several anti-angiogenic therapies are currently evaluated in advanced hepatocellular carcinomas. Few biological data are currently available from patients that may help understanding mechanisms of acquired resistance to these drugs. Herein, we report translational data from a post-treatment surgical specimen in a patient who experienced acquired resistance to sunitinib.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0168-8278
pubmed:author
pubmed:copyrightInfo
Copyright © 2011. Published by Elsevier B.V.
pubmed:issnType
Print
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1073-8
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma.
pubmed:affiliation
Department of Medical Oncology (APHP), Beaujon University Hospital, Paris 7 Diderot, Clichy, France.
pubmed:publicationType
Journal Article, Case Reports, Research Support, Non-U.S. Gov't